News & Notes
- Emory Start-up: RFS Pharma merges with Cocrystal Pharma ... View More
- Technology Transfer: What We do and Why it Matters, 2 Minute Video ... View More
- Emory Start-up: Clearside Biomedical, Inc. Announces Ongoing Results in Phase 1/2 Clinical Trial in Patients with Non-infectious Uveitis ... View More
- Emory Start-ups Prove Successful in Impact, Getting Inventions to Market ... View More
- Technology: One-Minute Point-of-Care Anemia Test Shows Promise in New Study ... View More
Therapeutic Protein Nanoparticles for the Treatment of Inflammatory Bowel Diseases
Andrew Neish, MD
Inflammatory bowel diseases (IBD) affect as many as 1.4 million Americans. IBD refers to chronic disorders of the intestinal tract, such as ulcerative colitis and Crohn’s disease. In people with IBD, the body’s immune system mistakes food, bacteria and other materials in the intestine for foreign substances. In turn, the immune system attacks the cells of the intestines.
Existing treatments for IBD come with serious side effects — Emory's Andrew Neish, MD, however, has a solution. Along with his team, Neish, a pathologist at Emory Healthcare, has discovered that a protein called AvrA, derived from the bacterial pathogen Salmonella, is capable of suppressing inflammation in the intestinal tract.